Core Insights - SS Innovations International, Inc. reported record quarterly revenue of $10.0 million, a 121.8% increase from $4.5 million in Q2 2024, driven by higher sales of the SSi Mantra 3 surgical robotic system [5][4] - Gross profit more than tripled to $5.9 million, reflecting a gross margin expansion to 59.1% from 31.9% in the same quarter last year [5][4] - The company narrowed its net loss to $0.3 million, compared to a net loss of $4.1 million in Q2 2024, indicating significant operational improvements [5][4] Second Quarter 2025 Overview - Revenue increased by 121.8% to $10.0 million from $4.5 million in Q2 2024 [5] - Gross margin expanded to 59.1% from 31.9% in Q2 2024 [5] - Gross profit rose 311.4% to $5.9 million from $1.4 million in Q2 2024 [5] - Net loss decreased to $0.3 million, or $(0.00) per diluted share, from a net loss of $4.1 million, or $(0.02) per diluted share, in Q2 2024 [5] First Half 2025 Overview - Revenue for the first half of 2025 increased by 85.6% to $15.1 million from $8.1 million in the first half of 2024 [5] - Gross margin expanded to 46.3% from 26.6% in the first half of 2024 [5] - Gross profit rose 223.3% to $7.0 million from $2.2 million in the first half of 2024 [5] - Net loss for the first half of 2025 was $5.9 million, or $(0.03) per diluted share, compared to a net loss of $14.0 million, or $(0.08) per diluted share, in the first half of 2024 [5] Business Highlights - SSi Mantra surgical robotic system installations totaled 23 in Q2 2025, a 130% increase from 10 installations in Q2 2024 [5] - Cumulative installed base of SSi Mantra systems reached 105 across seven countries, with cumulative surgeries totaling 4,657 [5] - The company plans to submit a 510(k) application for multiple indications for the SSi Mantra 3 to the FDA by the end of September 2025 [4][5] CEO Commentary - The CEO emphasized the company's commitment to expanding access to robotic surgery and highlighted the successful execution of strategic initiatives leading to strong revenue growth [4] - The SSi Mantra 3 system has achieved several "world firsts" in robotic telesurgery and cardiac procedures [4] - The company is on track for European Union CE marking certification by late 2025 [4]

Core Insights - SS Innovations International, Inc. has successfully completed the world's first intercontinental robotic cardiac telesurgery, showcasing the capabilities of its SSi Mantra 3 surgical robotic system [1][4][6] Company Overview - SS Innovations is dedicated to making robotic surgery affordable and accessible globally, with a focus on innovative surgical robotic technologies [1][8] - The company has received regulatory approval from India's Central Drugs Standard Control Organization for both teleproctoring and telesurgery, distinguishing it from other surgical robotic companies [7] Surgical Achievements - The recent cardiac procedure involved a robotic atrial septal defect closure performed remotely from Strasbourg, France to Indore, India, covering a distance of over 4,000 miles [2][3] - To date, SS Innovations has completed 35 telesurgeries, including 10 cardiac procedures, demonstrating the effectiveness of the SSi Mantra system in complex surgeries [6] Technological Features - The SSi Mantra surgical robotic system includes advanced features such as modular robotic arms, a 3D 4K monitor, and the ability to superimpose 3D diagnostic imaging models, enhancing surgical precision and safety [12]

Core Insights - SS Innovations International, Inc. has installed over 100 SSi Mantra surgical robotic systems across India and six other countries, with more than 5,000 surgical procedures performed to date, including 240 cardiac surgeries and 32 telesurgeries [1][2] - The company aims to democratize access to robotic surgery and plans to submit a De Novo application to the U.S. FDA for marketing approval of the SSi Mantra by the end of July 2025, while also pursuing CE marking certification in the European Union by late 2025 [2] Company Overview - SS Innovations develops innovative surgical robotic technologies with a focus on affordability and accessibility for a larger segment of the global population, featuring the SSi Mantra surgical robotic system and the SSi Mudra surgical instruments [3] - The company is headquartered in India and aims to expand its global presence with user-friendly and cost-effective surgical robotic solutions [3] Product Details - The SSi Mantra surgical robotic system is a modular, multi-arm system equipped with advanced technology features, including 3 to 5 robotic arms, a 3D 4K monitor, and the ability to superimpose 3D diagnostic imaging models [4] - It has been clinically validated in over 100 different types of surgical procedures, supporting various specialties, including cardiac surgery [4]

Core Insights - SS Innovations International, Inc. has successfully completed the world's first robotic telesurgery for weight loss using the SSi Mantra 3 surgical robotic system, marking a significant advancement in robotic surgery technology [1][4] Company Overview - SS Innovations is dedicated to making robotic surgery affordable and accessible globally, with a focus on innovative surgical robotic technologies [5] - The company is headquartered in India and aims to expand its global presence with user-friendly and cost-effective surgical robotic solutions [5] Technological Achievement - The robotic telesurgery bridged a distance of 560 miles between Gurugram and Indore, India, performed with zero perceptible lag and flawless precision [2][7] - The procedures involved two One-Anastomosis Gastric Bypass (OAGB) surgeries, showcasing the capabilities of the SSi Mantra 3 system [3][7] Leadership Commentary - Dr. Sudhir Srivastava, CEO, emphasized that this achievement bridges healthcare gaps and makes advanced surgical expertise accessible to remote regions [4] - Dr. Mohit Bhandari, who led the surgery, highlighted the potential of robotic telesurgery to redefine surgical care and improve access to healthcare [4] Future Vision - SS Innovations aims to continue refining its technology to enhance surgical efficiency and improve patient outcomes, particularly in underserved areas [4]

Core Insights - SS Innovations International, Inc. plans to submit a De Novo Classification Request to the FDA for the SSi Mantra 3 surgical robotic system in July 2025, aiming to enhance market access in the U.S. [1][2] Company Overview - SS Innovations is focused on developing innovative surgical robotic technologies to make robotic surgery affordable and accessible globally [6]. - The company has already marketed its SSi Mantra surgical robotic system in six countries and is pursuing further global expansion [5]. Product Performance - Since the launch of the SSi Mantra system in August 2022, 80 systems have been installed in 75 hospitals, with over 3,800 surgeries performed, including more than 200 robotic cardiac surgeries [3]. - The SSi Mantra 3 version, launched in June 2024, has seen 37 installations and over 750 multispecialty robotic surgical procedures, including 70 cardiac cases, with no device-related mortality or complications reported [3][4]. Clinical Validation - Real-world clinical data, validated by a leading contract research organization, supports the safety and efficacy of the SSi Mantra 3 for a variety of surgical procedures [4]. - The planned FDA submission will include applications for multispecialty indications such as urology, gynecology, general surgery, and thoracic and cardiac surgery [4]. Technological Features - The SSi Mantra Surgical Robotic System features a modular design with 3 to 5 robotic arms, an ergonomic surgeon command center, and advanced imaging capabilities, including a large 3D 4K monitor [7]. - It utilizes over 40 different types of robotic endo-surgical instruments to support various specialties, including cardiac surgery [7].

Company Overview - SS Innovations International, Inc. is focused on developing innovative surgical robotic technologies aimed at making robotic surgery affordable and accessible globally [4] - The company offers products such as the proprietary "SSi Mantra" surgical robotic system and the "SSi Mudra" surgical instruments, which support various surgical procedures including robotic cardiac surgery [4] Leadership Transition - Arvind Palaniappan has been appointed as the Interim Chief Financial Officer effective May 1, 2025, as part of a planned leadership transition [1] - Anup Sethi, the departing CFO, will remain available to advise the company during the transition period [1][2] - The company has initiated a search for a permanent successor for the CFO role [1] Executive Commentary - Dr. Sudhir Srivastava, Chairman and CEO, expressed confidence in Arvind Palaniappan's capabilities, highlighting his extensive experience in accounting and financial management [2] - Dr. Srivastava acknowledged Anup Sethi's contributions over the past seven years, particularly in building strong accounting and finance functions that supported the launch of over 80 surgical robotic systems [2] Profile of Interim CFO - Arvind Palaniappan is a Chartered Accountant with over 30 years of experience in accounting, financial management, risk consulting, and compliance [3] - He has served in various executive roles, including Managing Director at Accenture Solutions in India, and has been the principal of Trogon Consulting since February 2020 [3] Product Features - The SSi Mantra Surgical Robotic System features a modular design with 3 to 5 robotic arms, an ergonomic surgeon command center, and advanced imaging capabilities [5] - It has been clinically validated in India for over 100 different types of surgical procedures [5]